Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

Forty‐eight patients with resected Stages IIA and IIB melanoma were immunized with two tumor antigen epitope peptides derived from gp100209–217 (210M) (IMDQVPSFV) and tyrosinase368–376 (370D) (YMDGTMSQV) emulsified with incomplete Freund's adjuvant (IFA). Patients were assigned randomly to receive either peptides/IFA alone or with 250 μm of granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF) subcutaneously daily for 5 days to evaluate the toxicities and immune responses in either arm. Time to recurrence and survival were secondary end points.

[1]  S. Groshen,et al.  Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Marincola,et al.  Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination , 2001, The Journal of Immunology.

[4]  J. Berzofsky,et al.  Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. , 2001, International immunology.

[5]  I. Saeterdal,et al.  Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM‐CSF as adjuvant , 2001, Experimental dermatology.

[6]  J. Schlom,et al.  The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Albertini,et al.  Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Speiser,et al.  Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Schlom,et al.  Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. , 2001, Cancer research.

[11]  S. Hoffman,et al.  Plasmid Vaccine Expressing Granulocyte-Macrophage Colony-Stimulating Factor Attracts Infiltrates Including Immature Dendritic Cells into Injected Muscles1 , 2000, The Journal of Immunology.

[12]  D. Zelterman,et al.  Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit Model , 2000, Journal of Virology.

[13]  F. Marincola,et al.  Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells , 2000, The Journal of Immunology.

[14]  J. Schlom,et al.  Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes. , 2000, Cytokine.

[15]  S. Rosenberg,et al.  Long-Term Survival of Anti-Tumor Lymphocytes Generated by Vaccination of Patients With Melanoma With a Peptide Vaccine , 2000, Journal of immunotherapy.

[16]  M. Mihm,et al.  Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. , 2000, Cancer research.

[17]  S. Rosenberg.  Identification of cancer antigens: impact on development of cancer immunotherapies. , 2000, Cancer journal.

[18]  D. Schadendorf,et al.  Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma , 2000, Journal of immunotherapy.

[19]  P. Ljungman,et al.  Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[21]  J. Treanor,et al.  Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. , 1999, The Journal of infectious diseases.

[22]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[23]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[24]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Houghton,et al.  Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. , 1999, Cytokines, cellular & molecular therapy.

[26]  F. Marincola,et al.  Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.

[27]  S. Steinberg,et al.  Immune selection after antigen-specific immunotherapy of melanoma. , 1999, Surgery.

[28]  S. Rosenberg,et al.  Human tumor antigens for cancer vaccine development , 1999, Immunological reviews.

[29]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[30]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  S. Rosenberg,et al.  Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[32]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[33]  S. Henri,et al.  Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. , 1999, Vaccine.

[34]  J. Fagerberg,et al.  Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen , 1998, Cancer Immunology, Immunotherapy.

[35]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[36]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[38]  S. Kimura,et al.  CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. , 1998, Cancer research.

[39]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[40]  J. Berzofsky,et al.  Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. , 1997, Journal of immunology.

[41]  M. Ross,et al.  Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[43]  J. Cormier,et al.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.

[44]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[45]  H. Levitsky.  Tumors derived from antigen presenting cells. , 1996, Seminars in immunology.

[46]  H. Qin,et al.  Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. , 1996, Human gene therapy.

[47]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Levy,et al.  DNA immunization induces protective immunity against B–cell lymphoma , 1996, Nature Medicine.

[49]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[50]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[51]  D. Longo,et al.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. , 1996, Journal of immunology.

[52]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[53]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. , 1996, Blood.

[54]  M. Salgaller,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. , 1995, Cancer research.

[55]  C. Figdor,et al.  Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line , 1995, International journal of cancer.

[56]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  X. Sastre,et al.  Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.

[58]  C. Uyttenhove,et al.  Use of a skin test assay to determine tumor‐specific CD8+ T cell reactivity , 1994, European journal of immunology.

[59]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[61]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[62]  R. Scheule,et al.  Effects of continuous high dose rhgm‐csf infusion on human monocyte activity , 1993, American journal of hematology.

[63]  R. Levy,et al.  Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.

[64]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Rottem,et al.  Modulation of macrophage Fc gamma receptors by rGM-CSF. , 1993, Experimental hematology.

[66]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[67]  R. Zinkernagel,et al.  Skin test to assess virus-specific cytotoxic T-cell activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[69]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[70]  J. Kahn,et al.  Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  V. Hearing,et al.  Specific identification of an authentic clone for mammalian tyrosinase. , 1989, The Journal of biological chemistry.

[72]  V. Price,et al.  Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. , 1986, Science.